Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AND019 in ER+/HER2- Advanced Breast Cancer
NCT05187832Phase 1Recruiting
- Sponsor
- Kind Pharmaceuticals LLC
- Start
- Oct 2022
- Primary completion
- Nov 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AND019 in breast cancer, sponsored by Kind Pharmaceuticals LLC. Primary endpoints: Adverse Events at 12 weeks and Pharmacokinetics. Started Oct 2022; status: recruiting.
02
Drugs
AND019
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05187832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187832.